Legal & General Group’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-18,035
| Closed | -$1.75M | – | 3390 |
|
|
2019
Q3 | $1.75M | Buy |
18,035
+3,096
| +21% | +$310K | ﹤0.01% | 1778 |
|
|
2019
Q2 | $1.53M | Buy |
14,939
+650
| +5% | +$70.1K | ﹤0.01% | 1808 |
|
|
2019
Q1 | $1.63M | Buy |
14,289
+206
| +1% | +$15.1K | ﹤0.01% | 1775 |
|
|
2018
Q4 | $551K | Buy |
14,083
+3,782
| +37% | +$164K | ﹤0.01% | 2099 |
|
|
2018
Q3 | $562K | Hold |
10,301
| – | – | ﹤0.01% | 2110 |
|
|
2018
Q2 | $852K | Sell |
10,301
-1,572
| -13% | -$121K | ﹤0.01% | 1972 |
|
|
2018
Q1 | $791K | Buy |
11,873
+167
| +1% | +$9.64K | ﹤0.01% | 1981 |
|
|
2017
Q4 | $603K | Sell |
11,706
-44
| -0.4% | -$3.16K | ﹤0.01% | 2049 |
|
|
2017
Q3 | $1.05M | Buy |
11,750
+2,819
| +32% | +$214K | ﹤0.01% | 1850 |
|
|
2017
Q2 | $532K | Buy |
8,931
+1,286
| +17% | +$71.9K | ﹤0.01% | 2038 |
|
|
2017
Q1 | $408K | Sell |
7,645
-78
| -1% | -$4.63K | ﹤0.01% | 2082 |
|
|
2016
Q4 | $387K | Buy |
7,723
+2,048
| +36% | +$110K | ﹤0.01% | 2044 |
|
|
2016
Q3 | $337K | Buy |
5,675
+2,961
| +109% | +$171K | ﹤0.01% | 1879 |
|
|
2016
Q2 | $138K | Buy |
2,714
+1,394
| +106% | +$59.6K | ﹤0.01% | 1934 |
|
|
2016
Q1 | $39K | Hold |
1,320
| – | – | ﹤0.01% | 2518 |
|
|
2015
Q4 | $61K | Hold |
1,320
| – | – | ﹤0.01% | 2357 |
|
|
2015
Q3 | $52K | Hold |
1,320
| – | – | ﹤0.01% | 2431 |
|
|
2015
Q2 | $77K | Buy |
1,320
+950
| +257% | +$62.8K | ﹤0.01% | 2311 |
|
|
2015
Q1 | $28K | Buy |
+370
| New | +$21.3K | ﹤0.01% | 2676 |
|
Legal & General Group's ONCE Position: Q4 2019 in Review
Legal & General Group sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 18,035 shares — an estimated $1.75M sold.
Legal & General Group first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $1.75M in Q3 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Legal & General Group reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Legal & General Group sold 18,035 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $1.75M.
- Legal & General Group first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
- Legal & General Group's Spark Therapeutics, Inc. Common Stock position peaked at $1.75M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Legal & General Group's 13F filing for Q4 2019, filed 13 Feb 2020.